EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease

Christine R Andreasen, Andreas Andersen, Tina Vilsbøll

Diabetologia · 2023-10 · 66 (10) · 1846-1858

DOI: 10.1007/s00125-023-05966-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetologia, online erschienen am 27.07.2023. Verfasst von Christine R Andreasen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research, Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 101 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2HumansIncretinsGastric Inhibitory PolypeptideGlucagon-Like Peptide 1ObesityGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

Glucagon-like peptide-1Glucose-dependent insulinotropic polypeptideIncretinsNon-alcoholic fatty liver diseaseObesityReview

Substanzen

IncretinsGastric Inhibitory PolypeptideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Clinical Research, Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • Clinical Research, Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark. t.vilsboll@dadlnet.dk.
  • Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. t.vilsboll@dadlnet.dk.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. t.vilsboll@dadlnet.dk.

Zitieren

APA

Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023). The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Diabetologia, 66(10), 1846-1858. https://doi.org/10.1007/s00125-023-05966-9

Vancouver

Andreasen CR, Andersen A, Vilsbøll T. The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Diabetologia. 2023;66(10):1846-1858. doi:10.1007/s00125-023-05966-9

BibTeX
@article{Andreasen2023,
  author = {Andreasen, Christine R and Andersen, Andreas and Vilsbøll, Tina},
  title = {The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease},
  journal = {Diabetologia},
  year = {2023},
  volume = {66},
  number = {10},
  pages = {1846--1858},
  doi = {10.1007/s00125-023-05966-9}
}
Kostenlos starten →